Immunotherapy with checkpoint inhibitors, such as anti‐PDL1/‐PD1, has proven to be effective for the treatment of MCC; however, only about half of the MCC patients respond to immunotherapy, highlighting the need for novel therapeutic entry points (Kaufman et al, 2016; Nghiem et al, 2016). Here, CD274 is linked to Merkel cell skin cancer.